Primary Hyperoxaluria Market to Expand Significantly by 2034, States DelveInsight Report | Dicerna Pharmaceuticals, Inc., Allena Pharmaceuticals, Biocodex, Alnylam Pharmaceuticals

DelveInsight's "Primary Hyperoxaluria Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Primary Hyperoxaluria, historical and forecasted epidemiology as well as the Primary Hyperoxaluria market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Primary Hyperoxaluria market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Primary Hyperoxaluria Market Forecast https://www.delveinsight.com/sample-request/primary-hyperoxaluria-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Primary Hyperoxaluria Market Report:
• The Primary Hyperoxaluria market size was valued approximately USD 316 Million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In February 2025, An investigator-initiated trial evaluating YolTech Therapeutics' in vivo gene-editing therapy, designed as a life-long cure for a rare genetic disorder, demonstrated its ability to normalize key chemicals. The therapy, YOLT-203, was developed to treat primary hyperoxaluria type 1 (PH1), a condition caused by a genetic deficiency in the liver enzyme alanine-glyoxylate aminotransferase (AGT).
• In February 2025, The FDA granted orphan drug designation (ODD) and rare pediatric disease designation (RPDD) to Arbor Biotechnologies' gene-editing therapy, ABO-101, for the treatment of primary hyperoxaluria type 1 (PH1). These designations provide incentives such as tax credits, regulatory fee exemptions, potential market exclusivity, and eligibility for a pediatric priority review voucher upon approval of the therapy.
• In December 2024, Arbor BiotechnologiesTM, a biotech company advancing next-generation genetic medicines, announced that the FDA has approved its IND application for ABO-101, an innovative gene-editing therapy for primary hyperoxaluria type 1 (PH1). The redePHine Phase 1/2 trial will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ABO-101 in both adult and pediatric PH1 patients.
• In 2023, the United States represented the largest market for Primary Hyperoxaluria, making up about 89% of the total market size across the 7MM, compared to other major markets such as the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• In 2023, Germany held the largest market size for Primary Hyperoxaluria among European countries, reaching approximately USD 8 million, while Spain had the smallest market size, totaling around USD 4.3 million.
• The estimated market size for Primary Hyperoxaluria in Japan was approximately USD 1.3 million in 2023.
• According to DelveInsight's assessment, the estimated total prevalent cases of Primary Hyperoxaluria across the 7MM were approximately 12,000 in 2023.
• The US recorded the highest total diagnosed prevalent cases of Primary Hyperoxaluria in 2023, with approximately 2,000 cases, and these numbers are expected to increase in the future.
• In 2023, the UK reported the highest number of diagnosed prevalent cases of Primary Hyperoxaluria in Europe, with approximately 220 cases, followed by Germany with around 188 cases. Spain had the lowest prevalence, with about 100 cases.
• In 2023, Japan had the smallest number of diagnosed prevalent cases of Primary Hyperoxaluria, representing roughly 2.5% of the total cases across the 7MM.
• In 2023, the highest number of diagnosed prevalent cases of Primary Hyperoxaluria in the US was seen in the 0-4 age group (~780 cases), followed by the 5-9 age group (~470 cases). The fewest cases were observed in the 15-19 years age group.
• Key Primary Hyperoxaluria Companies: Alnylam Pharma, Allena Pharmaceuticals, Biocodex, Biocodex, Dicerna Pharmaceuticals, and others
• Key Primary Hyperoxaluria Therapies: OXLUMO (Lumasiran/ALN-GO1), RIVFLOZA (nedosiran/DCR-PHXC), Nedosiran (DCR-PHXC), ALLN-177, stiripentol (Diacomit), DCR-PHXC, and others
• The Primary Hyperoxaluria epidemiology based on gender analyzed that males contributes to higher diagnosed prevalent cases as compared to females
• The Primary Hyperoxaluria market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Primary Hyperoxaluria pipeline products will significantly revolutionize the Primary Hyperoxaluria market dynamics.

Primary Hyperoxaluria Overview
Primary Hyperoxaluria (PH) is a rare genetic disorder characterized by the overproduction of oxalate, a substance normally found in the body that combines with calcium to form calcium oxalate. In people with PH, this process occurs excessively due to defects in specific enzymes involved in the metabolic pathways that process glyoxylate and glycolate.

Get a Free sample for the Primary Hyperoxaluria Market Report:
https://www.delveinsight.com/report-store/primary-hyperoxaluria-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Primary Hyperoxaluria Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Primary Hyperoxaluria Epidemiology Segmentation:
The Primary Hyperoxaluria market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Prevalent Cases of Primary Hyperoxaluria in the 7MM
• Diagnosed Prevalent Cases of Primary Hyperoxaluria in the 7MM
• Gender-specific Cases of Diagnosed Prevalent Cases of Primary Hyperoxaluria in the 7MM
• Age-specific Cases of Diagnosed Prevalent Cases of Primary Hyperoxaluria in the 7MM
• Type-specific Cases of Diagnosed Prevalent Cases of Primary Hyperoxaluria in the 7MM

Download the report to understand which factors are driving Primary Hyperoxaluria epidemiology trends @ Primary Hyperoxaluria Epidemiology Forecast
https://www.delveinsight.com/sample-request/primary-hyperoxaluria-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Primary Hyperoxaluria Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Primary Hyperoxaluria market or expected to get launched during the study period. The analysis covers Primary Hyperoxaluria market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Primary Hyperoxaluria Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Primary Hyperoxaluria Therapies and Key Companies
• OXLUMO (Lumasiran/ALN-GO1): Alnylam Pharma
• RIVFLOZA (nedosiran/DCR-PHXC): Dicerna Pharmaceuticals, Inc.
•
• Nedosiran (DCR-PHXC): Dicerna Pharmaceuticals, Inc.
• ALLN-177: Allena Pharmaceuticals
• Stiripentol: Biocodex
• stiripentol (Diacomit): Biocodex
• DCR-PHXC: Dicerna Pharmaceuticals

Discover more about therapies set to grab major Primary Hyperoxaluria market share @ Primary Hyperoxaluria Treatment Market
https://www.delveinsight.com/sample-request/primary-hyperoxaluria-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Primary Hyperoxaluria Market Strengths
• The increasing prevalent population worldwide is likely to cause a surge in treatment options, and consequently, the market will witness a boost in upcoming years.
• The shortfall of approved therapies might provide good space for emerging therapies in the market.

Primary Hyperoxaluria Market Opportunities
• Limited approved treatment options offer a great opportunity for the investment and development of novel therapies
• Medications with better safety and effectiveness, which provide an optimum cure, are the current unmet need of the primary hyperoxaluria disease market.

Scope of the Primary Hyperoxaluria Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Primary Hyperoxaluria Companies: Alnylam Pharma, Allena Pharmaceuticals, Biocodex, Biocodex, Dicerna Pharmaceuticals, and others
• Key Primary Hyperoxaluria Therapies: OXLUMO (Lumasiran/ALN-GO1), RIVFLOZA (nedosiran/DCR-PHXC), Nedosiran (DCR-PHXC), ALLN-177, stiripentol (Diacomit), DCR-PHXC, and others
• Primary Hyperoxaluria Therapeutic Assessment: Primary Hyperoxaluria current marketed and Primary Hyperoxaluria emerging therapies
• Primary Hyperoxaluria Market Dynamics: Primary Hyperoxaluria market drivers and Primary Hyperoxaluria market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Primary Hyperoxaluria Unmet Needs, KOL's views, Analyst's views, Primary Hyperoxaluria Market Access and Reimbursement

To know more about Primary Hyperoxaluria companies working in the treatment market, visit @ Primary Hyperoxaluria Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/primary-hyperoxaluria-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Primary Hyperoxaluria Market Report Introduction
2. Executive Summary for Primary Hyperoxaluria
3. SWOT analysis of Primary Hyperoxaluria
4. Primary Hyperoxaluria Patient Share (%) Overview at a Glance
5. Primary Hyperoxaluria Market Overview at a Glance
6. Primary Hyperoxaluria Disease Background and Overview
7. Primary Hyperoxaluria Epidemiology and Patient Population
8. Country-Specific Patient Population of Primary Hyperoxaluria
9. Primary Hyperoxaluria Current Treatment and Medical Practices
10. Primary Hyperoxaluria Unmet Needs
11. Primary Hyperoxaluria Emerging Therapies
12. Primary Hyperoxaluria Market Outlook
13. Country-Wise Primary Hyperoxaluria Market Analysis (2020-2034)
14. Primary Hyperoxaluria Market Access and Reimbursement of Therapies
15. Primary Hyperoxaluria Market Drivers
16. Primary Hyperoxaluria Market Barriers
17. Primary Hyperoxaluria Appendix
18. Primary Hyperoxaluria Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Primary Hyperoxaluria Pipeline https://www.delveinsight.com/report-store/primary-hyperoxaluria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Primary Hyperoxaluria Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Primary Hyperoxaluria market. A detailed picture of the Primary Hyperoxaluria pipeline landscape is provided, which includes the disease overview and Primary Hyperoxaluria treatment guidelines.

Primary Hyperoxaluria Epidemiology https://www.delveinsight.com/report-store/primary-hyperoxaluria-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Primary Hyperoxaluria Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Primary Hyperoxaluria epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight
• Bone Densitometers Market: https://www.delveinsight.com/report-store/bone-densitometers-market
• Structural Heart Devices Market: https://www.delveinsight.com/report-store/structural-heart-devices-market-market
• Prosthetic Heart Valve Market: https://www.delveinsight.com/report-store/prosthetic-heart-valve-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market
• Cardiac Arrythmia Market: https://www.delveinsight.com/report-store/ambulatory-arrhythmia-monitoring-devices-market
• Alopecia Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Optical Coherence Tomography Devices Market: https://www.delveinsight.com/report-store/optical-coherence-tomography-oct-devices-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.